Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Aichi, Japan; Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan; Department of Nephrology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
Medical and Research Center for Nephrology and Transplantation, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Hyōgo, Japan.
Kidney Int. 2023 May;103(5):949-961. doi: 10.1016/j.kint.2023.01.008. Epub 2023 Feb 2.
While patients receiving dialysis therapy in the United States are more likely to develop cardiovascular disease (CVD) than those in Japan, direct comparisons of patients with predialysis chronic kidney disease (CKD) are rare. To study this, we compared various outcomes in patients with predialysis CKD using data from the Chronic Renal Insufficiency Cohort (CRIC) and CKD Japan Cohort (CKD-JAC) studies and determined mediators of any differences. Candidate mediators included left ventricular (LV) indices assessed by echocardiography. Among 3125 CRIC and 1097 CKD-JAC participants, the mean LV mass index (LVMI) and ejection fraction (EF) were 55.7 and 46.6 g/m and 54% and 65%, respectively (both significant). The difference in body mass index (32 and 24 kg/m, respectively) largely accounted for the differences in LVMI and C-reactive protein levels across cohorts. Low EF and high LVMI were significantly associated with subsequent CVD in both cohorts. During a median follow-up of five years, CRIC participants were at higher risk for CVD (adjusted hazard ratio [95% confidence interval]: 3.66 [2.74-4.89]) and death (4.69 [3.05-7.19]). A three-fold higher C-reactive protein concentration and higher phosphate levels in the United States cohort were moderately strong mediators of the differences in CVD. However, echocardiographic parameters were stronger mediators than these laboratory measures. LVMI, EF and their combination mediated the observed difference in CVD (27%, 50%, and 57%, respectively) and congestive heart failure (33%, 62%, and 70%, respectively). Thus, higher LV mass and lower EF, even in the normal range, were found to be predictive of CVD in CKD.
在美国接受透析治疗的患者比在日本接受透析治疗的患者更容易发生心血管疾病(CVD),但对透析前慢性肾脏病(CKD)患者进行直接比较的情况很少。为了研究这一点,我们使用慢性肾功能不全队列(CRIC)和 CKD 日本队列(CKD-JAC)的数据比较了透析前 CKD 患者的各种结局,并确定了任何差异的中介因素。候选中介因素包括超声心动图评估的左心室(LV)指数。在 3125 名 CRIC 和 1097 名 CKD-JAC 参与者中,LV 质量指数(LVMI)和射血分数(EF)分别为 55.7 和 46.6 g/m 和 54%和 65%(均有显著差异)。(分别为 32 和 24 kg/m)的体质量指数差异在很大程度上解释了两个队列中 LVMI 和 C 反应蛋白水平的差异。低 EF 和高 LVMI 与两个队列中随后的 CVD 显著相关。在中位随访 5 年期间,CRIC 参与者患 CVD 的风险更高(校正后的危险比[95%置信区间]:3.66[2.74-4.89])和死亡(4.69[3.05-7.19])。美国队列中 CRP 浓度高出三倍和磷酸盐水平较高是 CVD 差异的中度强中介因素。然而,超声心动图参数是比这些实验室测量更有力的中介因素。LVMI、EF 及其组合分别介导了 CVD(27%、50%和 57%)和充血性心力衰竭(33%、62%和 70%)观察到的差异。因此,即使在正常范围内,LV 质量增加和 EF 降低也被发现是 CKD 患者 CVD 的预测因素。